Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
EPS 컨센서스 7.16 · 매출 컨센서스 224.5억. 발표 후 실제치와 비교하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $1,328.05 · 30 analysts
Stored first · Google News · Yahoo Finance (English)
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 10. 29. | After market close (AMC) | $7.16 | — | — | $22.45B | — | Scheduled |
| FY2026 Q2 | 2026. 06. 30. | Time TBD | — | $7.94 | — | — | $22.97B | Reported |
| FY2026 Q1 | 2026. 04. 30. | Time TBD | — | $8.26 | — | — | $19.8B | Reported |
| FY2025 Q4 | 2026. 02. 12. | Time TBD | — | — | — | — | $19.29B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 10. 12. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 10. 08. | Cantor Fitzgerald | — | Maintain | Overweight → Overweight | — | Cantor Fitzgerald: Overweight |
| 2026. 10. 07. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 09. 29. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 09. 22. | TD Cowen | — | Maintain | Buy → Buy | — | TD Cowen: Buy |
| 2026. 09. 18. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
As of FY2026Q2 · Source: SEC/DART + price data
No holdings data to show.
